+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Upadacitinib Market by Form, Therapeutic Area, End-Users, Distribution Channel - Global Forecast to 2030- Product Image
Upadacitinib Market by Form, Therapeutic Area, End-Users, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Upadacitinib Market by Form, Therapeutic Area, End-Users, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6090163
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Upadacitinib market is rapidly evolving amid advancements in immunology, increasing clinical adoption, and shifting regulatory and supply chain dynamics. For senior decision-makers, understanding current trends, competitive positioning, and future risks is essential to capture new value opportunities and inform strategic planning.

Market Snapshot: Upadacitinib Market Size & Growth

The Upadacitinib Market grew from USD 303.47 million in 2024 to USD 325.20 million in 2025. It is expected to continue growing at a CAGR of 7.41%, reaching USD 466.22 million by 2030.

Scope & Segmentation

This report delivers an in-depth breakdown of the market and its operative landscape by product format, indication, end-user, distribution channel, region, and major industry players.

  • Form: Solution; Tablet
  • Therapeutic Area: Ankylosing Spondylitis; Atopic Dermatitis; Crohn's Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis
  • End-Users: Hospitals & Clinics; Outpatient Care; Specialty Clinics
  • Distribution Channel: Offline; Online
  • Region: Americas (including United States, Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies: AbbVie Inc.; Bayer AG; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Cipla Limited; Daiichi Sankyo Company, Limited; GlaxoSmithKline plc; Incyte Corporation; Merck & Co., Inc.; Pfizer Inc; Regeneron Pharmaceuticals, Inc.; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited

Key Takeaways for Decision-Makers

  • The primary keyword, Upadacitinib, anchors a shift in care by offering a potent oral Janus kinase inhibitor that expands choice across several immune-mediated diseases.
  • Recent clinical advances support broadening therapeutic use and off-label investigations, with solution and tablet formats addressing distinct settings and patient requirements.
  • Precision medicine is advancing within this market, using biomarker-driven patient selection to improve outcomes and optimize therapy alignment.
  • Integration of digital health technologies enhances patient adherence and real-world data collection, facilitating outcome-driven reimbursement models.
  • The competitive landscape is marked by established pharmaceutical leaders and smaller biotech entrants driving formulation innovation and competing on late-stage development programs.
  • Portfolio diversification and strategic partnerships are key to defensive positioning, particularly as biosimilar and generic JAK inhibitors approach market entry.

Tariff Impact

New tariffs implemented in the United States in 2025 will affect Upadacitinib’s production and distribution costs, particularly due to increased duties on specific pharmaceutical ingredients and raw materials. Strategic operational adjustments—including revisiting supplier agreements and evaluating location flexibility—will become increasingly vital for protecting margin and continuity of supply. Manufacturers must also be proactive in communicating with payers and adjusting pricing models to maintain accessibility and competitive standing.

Methodology & Data Sources

This report employs a rigorous methodology combining primary interviews with key opinion leaders, payers, procurement experts, and patient advocacy representatives across core regions. Secondary research includes peer-reviewed journals, regulatory filings, and industry reports. Quantitative models and proprietary datasets underpin competitive benchmarking and trend analysis, all verified by cross-validation with an expert panel.

Why This Report Matters

  • Provides actionable, evidence-based insights into evolving clinical, regulatory, and supply chain trends shaping the Upadacitinib market.
  • Guides strategic decision-making for portfolio segmentation, alliance-building, and operational resilience amid emergent risks.
  • Enables market entrants and established leaders to benchmark against innovation trajectories and adapt business models for upcoming competitive pressures.

Conclusion

The Upadacitinib market presents an intricate blend of innovation, competition, and operational challenges. Organizations that respond with data-driven strategy and agile adaptation will be best positioned to realize both near-term efficiencies and sustained long-term growth.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Upadacitinib Market, by Form
8.1. Introduction
8.2. Solution
8.3. Tablet
9. Upadacitinib Market, by Therapeutic Area
9.1. Introduction
9.2. Ankylosing Spondylitis
9.3. Atopic Dermatitis
9.4. Crohn's Disease
9.5. Psoriatic Arthritis
9.6. Rheumatoid Arthritis
9.7. Ulcerative Colitis
10. Upadacitinib Market, by End-Users
10.1. Introduction
10.2. Hospitals & Clinics
10.3. Outpatient Care
10.4. Speciality Clinics
11. Upadacitinib Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Americas Upadacitinib Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Upadacitinib Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Upadacitinib Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Bayer AG
15.3.3. Boehringer Ingelheim GmbH
15.3.4. Bristol-Myers Squibb Company
15.3.5. Cipla Limited
15.3.6. Daiichi Sankyo Company, Limited
15.3.7. GlaxoSmithKline plc
15.3.8. Incyte Corporation
15.3.9. Merck & Co., Inc.
15.3.10. Pfizer Inc
15.3.11. Regeneron Pharmaceuticals, Inc.
15.3.12. Sun Pharmaceutical Industries Ltd.
15.3.13. Takeda Pharmaceutical Company Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. UPADACITINIB MARKET MULTI-CURRENCY
FIGURE 2. UPADACITINIB MARKET MULTI-LANGUAGE
FIGURE 3. UPADACITINIB MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL UPADACITINIB MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL UPADACITINIB MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL UPADACITINIB MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL UPADACITINIB MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL UPADACITINIB MARKET SIZE, BY END-USERS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL UPADACITINIB MARKET SIZE, BY END-USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES UPADACITINIB MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES UPADACITINIB MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UPADACITINIB MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. UPADACITINIB MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. UPADACITINIB MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL UPADACITINIB MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL UPADACITINIB MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL UPADACITINIB MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL UPADACITINIB MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL UPADACITINIB MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL UPADACITINIB MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL UPADACITINIB MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL UPADACITINIB MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL UPADACITINIB MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL UPADACITINIB MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL UPADACITINIB MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL UPADACITINIB MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL UPADACITINIB MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL UPADACITINIB MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL UPADACITINIB MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES UPADACITINIB MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 33. CANADA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 34. CANADA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 35. CANADA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 36. CANADA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. MEXICO UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 38. MEXICO UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 39. MEXICO UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 40. MEXICO UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 51. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 55. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 56. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 57. UNITED KINGDOM UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. GERMANY UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 59. GERMANY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 60. GERMANY UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 61. GERMANY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. FRANCE UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 63. FRANCE UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 64. FRANCE UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 65. FRANCE UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. RUSSIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 67. RUSSIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 68. RUSSIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 69. RUSSIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. ITALY UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 71. ITALY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 72. ITALY UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 73. ITALY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. SPAIN UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 75. SPAIN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 76. SPAIN UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 77. SPAIN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 79. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 80. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 81. UNITED ARAB EMIRATES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 88. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 89. SOUTH AFRICA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. DENMARK UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 91. DENMARK UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 92. DENMARK UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 93. DENMARK UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. NETHERLANDS UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 95. NETHERLANDS UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 96. NETHERLANDS UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. NETHERLANDS UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. QATAR UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 99. QATAR UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 100. QATAR UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 101. QATAR UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. FINLAND UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 103. FINLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 104. FINLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 105. FINLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. SWEDEN UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 107. SWEDEN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 108. SWEDEN UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 109. SWEDEN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 113. NIGERIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. EGYPT UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 115. EGYPT UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 116. EGYPT UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 117. EGYPT UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. TURKEY UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 119. TURKEY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 120. TURKEY UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 121. TURKEY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. ISRAEL UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. NORWAY UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 127. NORWAY UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 128. NORWAY UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 129. NORWAY UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. POLAND UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 131. POLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 132. POLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 133. POLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC UPADACITINIB MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 143. CHINA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 144. CHINA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 145. CHINA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 146. CHINA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. INDIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 148. INDIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 149. INDIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 150. INDIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. JAPAN UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 152. JAPAN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 153. JAPAN UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 154. JAPAN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. THAILAND UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 168. THAILAND UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 169. THAILAND UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 170. THAILAND UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 173. PHILIPPINES UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 174. PHILIPPINES UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 182. SINGAPORE UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN UPADACITINIB MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN UPADACITINIB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN UPADACITINIB MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN UPADACITINIB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. UPADACITINIB MARKET SHARE, BY KEY PLAYER, 2024
TABLE 192. UPADACITINIB MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Upadacitinib market report include:
  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Pfizer Inc
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 325.2 Million
Forecasted Market Value ( USD ) by 2030 $ 466.22 Million
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Upadacitinib Global Market Report 2025 - Product Image

Upadacitinib Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Vitiligo Pipeline Analysis Report - Product Image

Vitiligo Pipeline Analysis Report

  • Report
  • 150 Pages
  • Global
From
Vitiligo Drug Pipeline Analysis Report 2025 - Product Image

Vitiligo Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Crohn's Disease Therapeutics Market by Therapy Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Crohn's Disease Therapeutics Market by Therapy Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Alopecia Areata: Opportunity Assessment and Forecast to 2033 - Product Image

Alopecia Areata: Opportunity Assessment and Forecast to 2033

  • Report
  • 81 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.